查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1386930

癌症基因治療市場報告：2030 年趨勢、預測與競爭分析

Cancer Gene Therapy Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

癌症基因治療的趨勢和預測

預計到 2030 年，全球癌症基因治療市場將達到 74 億美元，2024 年至 2030 年年複合成長率為 17.4%。這個市場的主要促進因素是基因治療需求的增加、癌症治療和皮膚病技術發展的進步以及癌症發病率的增加。全球癌症基因治療市場前景廣闊，醫院、生物製藥、科研機構市場蘊藏商機。

癌症基因治療市場洞察

Lucintel 預測，由於遏制癌症成長的研發活動增加，基因引導免疫療法將在預測期內保持最大的市場規模。

在這個市場中，由於癌症發病率不斷上升，以及領先的生物製藥公司擴大採用成分基因治療解決方案來設計癌症治療方法。

由於政府機構對創新療法的研究經費增加，以及對新療法的需求不斷成長，以解決該地區迅速增加的癌症病例數量，北美在預測期內仍將是最大的地區。

本報告回答了 11 個關鍵問題：

  • Q.1. 細分市場中最有前途和高成長的機會是什麼？
  • Q.2.哪個細分市場將以更快的速度成長？為什麼？
  • Q.3.您認為哪些地區未來會出現更快的成長？為什麼？
  • Q.4. 影響市場動態的主要因素有哪些？市場的主要挑戰和商業風險是什麼？
  • Q.5. 這個市場的商業風險和競爭威脅是什麼？
  • Q.6.這個市場有哪些新趨勢？為什麼？
  • Q.7.市場客戶需求有何改變？
  • Q.8. 該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10. 該市場上的競爭產品有哪些？由於材料或產品替代而導致市場佔有率下降的威脅有多大？
  • Q.11.過去年度發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球癌症基因治療市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球癌症基因治療市場趨勢（2018-2023）與預測（2024-2030）
  • 按治療分類的全球癌症基因治療市場
    • 溶瘤病毒療法
    • 基因誘導的免疫治療
    • 基因轉移
    • 其他
  • 按適應症分類的全球癌症基因治療市場
    • 乳癌
    • 卵巢癌
    • 肝癌
    • 胰臟癌
    • 肺癌
    • 其他
  • 按最終用途分類的全球癌症基因治療市場
    • 醫院
    • 生物製藥公司
    • 調查機構
    • 其他

第4章 2018-2030年分地區市場趨勢及預測分析

  • 全球癌症基因治療市場按地區分類
  • 北美癌症基因治療市場
  • 歐洲癌症基因治療市場
  • 亞太地區癌症基因治療市場
  • 其他區域癌症基因治療市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球癌症基因治療市場的治療成長機會
    • 全球癌症基因治療市場成長機會（按適應症）
    • 全球癌症基因治療市場最終用途的成長機會
    • 全球癌症基因治療市場按地區成長機會
  • 全球癌症基因治療市場新趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球癌症基因治療市場的產能
    • 全球癌症基因治療市場的合併、收購和合資企業
    • 認證和許可

第7章 主要企業概況

  • Abeona Therapeutics
  • Asklepios BioPharmaceutical
  • Altor Bioscience
  • Bluebird bio
  • BioCancell
  • Celgene
  • Elevate Bio
  • GlaxoSmithKline
  • Genelux
  • GenVec
簡介目錄

Cancer Gene Therapy Trends and Forecast

The future of the global cancer gene therapy market looks promising with opportunities in the hospital, biopharmaceutical company, and research institute markets. The global cancer gene therapy market is expected to reach an estimated $7.4 billion by 2030 with a CAGR of 17.4% from 2024 to 2030. The major drivers for this market are increasing demand for gene therapy, advance technological development in cancer treatment and daignosis, and growing incidence of cancer cases.

A more than 150-page report is developed to help in your business decisions.

Cancer Gene Therapy by Segment

The study includes a forecast for the global cancer gene therapy by therapy, indication, end use, and region.

Cancer Gene Therapy Market by Therapy [Shipment Analysis by Value from 2018 to 2030]:

  • Oncolytic Virotherapy
  • Gene Induced Immunotherapy
  • Gene Transfer
  • Others

Cancer Gene Therapy Market by Indication [Shipment Analysis by Value from 2018 to 2030]:

  • Breast Cancer
  • Ovarian Cancer
  • Liver Cancer
  • Pancreatic Cancer
  • Lung Cancer
  • Others

Cancer Gene Therapy Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Biopharmaceutical Companies
  • Research Institutes
  • Others

Cancer Gene Therapy Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Cancer Gene Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cancer gene therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cancer gene therapy companies profiled in this report include-

  • Abeona Therapeutics
  • Asklepios Biopharmaceutical
  • Altor Bioscience
  • Bluebird Bio
  • Biocancell
  • Celgene
  • Elevate Bio
  • Glaxosmithkline
  • Genelux
  • Genvec

Cancer Gene Therapy Market Insights

Lucintel forecasts that gene induced immunotherapy will remain the largest sgement over the forecast period due to increasing research & development activities to lower the proliferation of cancer.

Within this market, biopharmaceutical companies will remain the largest segment due to increasing prevelance of cancer and growing adoption of elemental gene therapy solutions by major biopharmaceutical companies for designing cancer treatment regimens.

North America will remain the largest region over the forecast period due to increasing research funding for innovative therapeutics by government entities and the rising demand for novel therapeutics to address the escalating number of cancer cases in the region.

Features of the Global Cancer Gene Therapy Market

Market Size Estimates: Cancer gene therapy market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Cancer gene therapy market size by therapy, indication, end use, and region in terms of value ($B).

Regional Analysis: Cancer gene therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different therapies, indications, end uses, and regions for the cancer gene therapy market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cancer gene therapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the cancer gene therapy market size?

Answer: The global cancer gene therapy market is expected to reach an estimated $7.4 billion by 2030.

Q.2 What is the growth forecast for cancer gene therapy market?

Answer: The global cancer gene therapy market is expected to grow with a CAGR of 17.4% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the cancer gene therapy market?

Answer: The major drivers for this market are increasing demand for gene therapy, advance technological development in cancer treatment and daignosis, and growing incidence of cancer cases.

Q4. What are the major segments for cancer gene therapy market?

Answer: The future of the cancer gene therapy market looks promising with opportunities in the hospital, biopharmaceutical company, and research institute markets.

Q5. Who are the key cancer gene therapy market companies?

Answer: Some of the key cancer gene therapy companies are as follows:

  • Abeona Therapeutics
  • Asklepios Biopharmaceutical
  • Altor Bioscience
  • Bluebird Bio
  • Biocancell
  • Celgene
  • Elevate Bio
  • Glaxosmithkline
  • Genelux
  • Genvec

Q6. Which cancer gene therapy market segment will be the largest in future?

Answer: Lucintel forecasts that gene induced immunotherapy will remain the largest sgement over the forecast period due to increasing research & development activities to lower the proliferation of cancer.

Q7. In cancer gene therapy market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to increasing research funding for innovative therapeutics by government entities and the rising demand for novel therapeutics to address the escalating number of cancer cases in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the cancer gene therapy market by therapy (oncolytic virotherapy, gene induced immunotherapy, gene transfer, and others), indication (breast cancer, ovarian cancer, liver cancer, pancreatic cancer, lung cancer, and others), end use (hospitals, biopharmaceutical companies, research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Cancer Gene Therapy Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Cancer Gene Therapy Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Cancer Gene Therapy Market by Therapy
    • 3.3.1: Oncolytic Virotherapy
    • 3.3.2: Gene Induced Immunotherapy
    • 3.3.3: Gene Transfer
    • 3.3.4: Others
  • 3.4: Global Cancer Gene Therapy Market by Indication
    • 3.4.1: Breast Cancer
    • 3.4.2: Ovarian Cancer
    • 3.4.3: Liver Cancer
    • 3.4.4: Pancreatic Cancer
    • 3.4.5: Lung Cancer
    • 3.4.6: Others
  • 3.5: Global Cancer Gene Therapy Market by End Use
    • 3.5.1: Hospitals
    • 3.5.2: Biopharmaceutical companies
    • 3.5.3: Research Institutes
    • 3.5.4: others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Cancer Gene Therapy Market by Region
  • 4.2: North American Cancer Gene Therapy Market
    • 4.2.2: North American Cancer Gene Therapy Market by End Use: Hospitals, Biopharmaceutical companies, Research Institutes, and others
  • 4.3: European Cancer Gene Therapy Market
    • 4.3.1: European Cancer Gene Therapy Market by Therapy: Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer, and Others
    • 4.3.2: European Cancer Gene Therapy Market by End Use: Hospitals, Biopharmaceutical companies, Research Institutes, and others
  • 4.4: APAC Cancer Gene Therapy Market
    • 4.4.1: APAC Cancer Gene Therapy Market by Therapy: Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer, and Others
    • 4.4.2: APAC Cancer Gene Therapy Market by End Use: Hospitals, Biopharmaceutical companies, Research Institutes, and others
  • 4.5: ROW Cancer Gene Therapy Market
    • 4.5.1: ROW Cancer Gene Therapy Market by Therapy: Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer, and Others
    • 4.5.2: ROW Cancer Gene Therapy Market by End Use: Hospitals, Biopharmaceutical companies, Research Institutes, and others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Cancer Gene Therapy Market by Therapy
    • 6.1.2: Growth Opportunities for the Global Cancer Gene Therapy Market by Indication
    • 6.1.3: Growth Opportunities for the Global Cancer Gene Therapy Market by End Use
    • 6.1.4: Growth Opportunities for the Global Cancer Gene Therapy Market by Region
  • 6.2: Emerging Trends in the Global Cancer Gene Therapy Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Cancer Gene Therapy Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cancer Gene Therapy Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Abeona Therapeutics
  • 7.2: Asklepios BioPharmaceutical
  • 7.3: Altor Bioscience
  • 7.4: Bluebird bio
  • 7.5: BioCancell
  • 7.6: Celgene
  • 7.7: Elevate Bio
  • 7.8: GlaxoSmithKline
  • 7.9: Genelux
  • 7.10: GenVec